A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis
NCT06752603 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2026-03-30
Summary
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Hunner Type Interstitial Cystitis
Conditions
- Hunner Type Interstitial Cystitis
Interventions
- DRUG
-
ONO-1110
ONO-1110 tablets once a day
- DRUG
-
Placebo tablets once daily
Sponsors & Collaborators
-
Ono Pharmaceutical Co. Ltd
lead INDUSTRY
Principal Investigators
-
Project Leader · Ono Pharmaceutical Co. Ltd
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-02
- Primary Completion
- 2026-09-30
- Completion
- 2026-11-30
Countries
- Japan
Study Locations
More Related Trials
-
A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
NCT00410514 ·Status: COMPLETED ·Phase: PHASE2
-
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
NCT04562090 ·Status: COMPLETED ·Phase: PHASE4
-
A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
NCT00840645 ·Status: COMPLETED ·Phase: PHASE3
-
Study of ONO-8539 in Patients With Overactive Bladder
NCT00876421 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
NCT00742833 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder
NCT00512785 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of YM178 in Patients With Symptomatic Overactive Bladder
NCT00527033 ·Status: COMPLETED ·Phase: PHASE2
-
Study of V117957 in Overactive Bladder Syndrome
NCT06024642 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964 ·Status: COMPLETED ·Phase: PHASE3
-
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
NCT00231790 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
NCT00658684 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00689104 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
NCT00290563 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder
NCT01003405 ·Status: WITHDRAWN ·Phase: PHASE3
-
Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
NCT03044912 ·Status: UNKNOWN ·Phase: PHASE3
-
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
NCT01745094 ·Status: COMPLETED ·Phase: PHASE4
-
Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
NCT02981459 ·Status: WITHDRAWN ·Phase: PHASE4
-
Acupuncture Combined With Mirabegron in the Treatment of OAB
NCT06181019 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
NCT00561951 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
NCT01157377 ·Status: COMPLETED ·Phase: PHASE2
-
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
NCT03059134 ·Status: COMPLETED ·Phase: PHASE3
-
Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
NCT05188742 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
NCT00171184 ·Status: COMPLETED ·Phase: PHASE4